Ambryon Biosciences

CMV early enhancer/chicken beta-actin/SV40 intron (CBA) promoter

Synthetic hybrid promoter combining the CMV immediate-early enhancer, the chicken β-actin promoter, and an SV40 intron; drives strong, ubiquitous constitutive expression in mammalian cells. Compact ~800 bp variant used in AAV and other gene-therapy vectors, distinct from the larger CAG promoter, which substitutes a rabbit β-globin intron for the SV40 intron.

Relative StrengthStrong
OriginCMV enhancer + chicken β-actin promoter + SV40 intron (synthetic)
Expression PatternConstitutive

Characteristics

CMV IE enhancer fused upstream of the chicken β-actin promoter, with an SV40 intron inserted downstream of the transcription start site (~800 bp total). In AAV vectors delivered by portal vein injection in mice, this CMV/β-actin cassette produces 9.5-fold higher expression than an EF1α promoter and 137-fold higher expression than the CMV promoter/enhancer alone (Xu et al. 2001). In rat hippocampal and spinal cord slice cultures transduced by AAV9, it drives mostly ubiquitous, high-level neural expression but yields far fewer GFP-positive spinal motor neurons (~2-4 per 40-µm section) than the CMV promoter or the hybrid-intron CBh variant (~30-40 per section) (Gray et al. 2011).

Applications

Drives therapeutic and reporter transgenes in AAV vectors for liver-directed gene therapy, including hepatic expression of human factor X in mice (Xu et al. 2001), and in AAV9 vectors for CNS/PNS gene delivery, where it produces widespread neuronal and glial expression but weak motor neuron transduction (Gray et al. 2011).

Limitations

Drives poor expression in spinal and brainstem motor neurons relative to the CMV promoter or the CBh hybrid-intron variant, a documented effect of the SV40 intron in this cassette (Gray et al. 2011). At ~800 bp, still adds meaningful size to AAV constructs with a ~4.7 kb packaging limit.

Sequence850 bp

Sign in to view the full sequence.

Sign in

Identifiers & revision